Compare NIO Inc. (NIO) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NIO Inc. vs TG Therapeutics Inc — how do they compare? NIO Inc. trades at $3.58 (market cap $8.62B), while TG Therapeutics Inc trades at $55.37 (market cap $8.16B). The key difference: NIO Inc. and TG Therapeutics Inc are close in size by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold NIO Inc. for 81 Days and TG Therapeutics Inc for 16 Days on average.
| NIO | TGTX | |
|---|---|---|
Market Cap | $8.62B | $8.16B |
Volume | 39,648,517 | 1,735,121 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.46 | $59.06 |
52-Week Low | $3.37 | $26.94 |
Typical Hold Time | 81 Days | 16 Days |
Enterprise Value | $6.52B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NIO trades at $3.58, up 1.13% in the last session but near a 52-week low amid a bearish technical trend. The company reported Q3 2026 deliveries up 25.4% and recently formed a strategic battery-swap partnership with Geely, yet it continues to post net losses with a -4.17% net margin. Analyst consensus is a 'Buy' with a $6.23 price target, but high debt and negative cash flows pose challenges.
The outlook remains cautious; revenue growth and partnership potential offer upside, but persistent losses, cash burn, and intense EV competition present significant risks. Investors should weigh the long-term battery-swap network expansion against near-term financial instability and market volatility.
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
